Abstract: Separation of morphine and its impurities (related substances specified in relevant European Pharmacopoeia monographs, as well as the other naturally occurring coextracted alkaloids) was obtained within a close retention window on a reverse phase HPLC column, eluted with optimized gradient, consisting of methanol and 5 mM ammonium formate, adjusted to pH 10.2. Systematic optimization of the chromatographic conditions was carried out using design of experiments. According to their mass spectra, known and specified impurities were identified and tentative structures for unknown impurities were proposed. MS analyses were performed in positive ionization mode using heated electrospray ionization. Fragmentation patterns of the eluted compounds under optimized mass spectrometry conditions indicated that all detected impurities are structurally related to morphine.
Introduction
Impurity profiling is strongly related to detecting, understanding the mechanism of action, and preventing side effects of medicines; therefore, analytical monitoring of impurities in active pharmaceutical ingredients (APIs) is a key component of drug development. 1, 2 This indicates that the quality control of APIs should always be supported by additional purity profiling, based on the information obtained from the manufacturing process. Furthermore, the impurity profiling represents part of an analytical strategy used for combating falsification of medicines. 4−6 Our previous work demonstrated that profound understanding of impurity profile is the key to a better understanding of the origin and differentiation of API samples.
7−9
Considering the fact that morphine is isolated from a natural product, the profile of impurities largely encompasses organic compounds with similar structures. It is very likely that the most abundant poppy alkaloids would be coextracted under extraction conditions of morphine. Organic impurities with similar structure to morphine can be characterized using HPLC, as suggested in the European Pharmacopoeia (Ph.Eur). 10 However, the list of specified impurities does not indicate other alkaloids (e.g., thebaine, noscapine, papaverine), their biosynthetic intermediates, degradation products, and other classes of alkaloids. Since HPLC retention times * Correspondence: apetkovska@alkaloid.com.mk may vary, uncertainty can arise as to whether a peak in a new retention time means a new impurity. Therefore, when impurity standards are not available, the method should provide online characterization, such as mass spectrometry (MS), as a detection tool in further determination of the unknown and unspecified impurities.
This work attempts to assess the ability of LC-MS n to generate characteristic impurity fragmentation pathways, composed of a molecular ion mass, plus at least three fragmentation steps. 11, 12 Our previous research on API authentication and prevention of falsification, based on the impurities detected in morphine samples 7 and assessment of the qualitative profile of alkaloids in poppy straw, 13−15 pointed out the necessity of online characterization of the present analytes. Thus the aim of this part of the research was to advance LC method identification performances of a suitable 'MS friendly' HPLC method for separation and identification of morphine and its known and unknown related substances and possible degradation products, using a welldesigned strategy for optimization and robustness verification.
16−19
2. Results and discussion
Optimization of the chromatographic conditions
In order to optimize the chromatographic conditions, 2 3 central composite face centered design of experiments (CCFC DoE) was employed, which involved a set of 11 planned experiments, and investigation of two experimental factors: buffer concentration (x1), in a range from 1 to 10 mM, and buffer pH value (x2), in a range from 9.0 to 10.2. The chromatographic response was assessed through the critical resolutions (between morphine and impurity E and between morphine and impurity B) and the retention factor of impurity F. The results obtained during the method optimization are summarized in Table 1 . The effects of the different experimental conditions on the defined chromatographic responses are shown through the normalized coefficients of the CCFC design ( Figure 1 ). The alteration of the chromatographic responses over the defined area of the experimental factors was assessed using response surface methodology (RSM) (Figure 2 ). The results of the chemometric experiments showed that all factors affected the chromatographic parameters. Critical resolution between impurity E and morphine was perceived, and impurity F was eluted in the column void time (1.4 min). By increasing the buffer concentration and the pH of the buffer, impurity E/morphine resolution ( Figure 2a ) and impurity B/morphine resolution (Figure 2b ) was enhanced. The retention factor (k ′ value) for the first eluted peak (impurity F) was increased (above 1, which was set as target minimum value) by increasing the buffer concentration and decreasing the buffer pH value (Figure 2c ). However, the lowest possible buffer concentration is desirable for better sensitivity of the mass spectrometer. As for the pH value, attention should be paid to the column stability. According to the RSM results shown in Figure 3 , the chromatographic conditions were optimized. Since the operational pH range of the column was to 11.5, the maximal value was chosen (10.2), considering also the buffer capacity. For the buffer concentration, a mid value was chosen, since both critical resolutions were above the target value of 2.0 (Figures 3a and 3b) . As for the retention factor of impurity F, the content of organic solvent (MeOH) was decreased in order to keep the value above 1.0 (Figure 3c ). 
Method validation
Under the proposed chromatographic conditions all analytes were completely separated ( Figure 4 ). Results from method validation, in accordance with International Conference on Harmonization (ICH) guidelines Q2 R1 20 showed satisfactory specificity, linearity, sensitivity, precision, accuracy, and robustness. The number of theoretical plates (N) for all analytes (N > 5000) indicates a good separation efficiency of the applied column.
Capacity factor values for all peaks were between 2 and 10. All peaks have good shape, with symmetry factor (As) values between 0.8 and 1.2.
The linearity of the method was demonstrated for morphine reference solutions ranging from 1.275 to 11.475 µ g/mL (0.05%-0.45% of the morphine working concentration). The results obtained from the regression analysis of the peak area (y) versus concentration (x) data indicated that the method was linear (y = 13.931x -3.8973, R 2 = 0.9999).
The limit of detection (LOD) and limit of quantification (LOQ) were determined from the residual standard deviation of the regression line (σ) and the slope (S) in the concentration range from 1.275 to 11.475 µ g/mL (0.05%-0.45% of the morphine working concentration). The LOD for morphine (3.3 σ /S) is 0.15 µ g/mL (0.006% of the morphine working concentration), which is within the acceptance criteria (LOD was ≤ 0.05% of the morphine working concentration (Ph.Eur disregard limit (10)), i.e. ≤ 1.275 µ g/mL). The LOQ value (10 σ /S) was 0.44 µ g/mL (0.017% of the morphine working concentration), which is much less than level of specification (0.2% of the morphine working concentration).
The repeatability was performed by analyzing six replicate injections of an impurity standard solution at 100% of the specified limit with respect to the working strength of API (0.2% of the morphine working concentration for each impurity, except for impurity B: 0.4% of the morphine working concentration). The percentage relative standard deviations of peak areas (n = 6) were less than 2.0% for each impurity, which indicated acceptable repeatability of the method. Additionally, precision at LOQ was performed by analyzing three replicate injections of a standard solution of morphine at LOQ level and the percentage relative standard deviation was less than 5.0%.
The accuracy of the method was assessed by comparison of the results of the proposed analytical procedure with those of a second well-characterized procedure, i.e. method for related substances described in Ph.Eur monographs on morphine hydrochloride trihydrate (04/2008:0097) and morphine sulfate pentahydrate (04/2008:1244), since the impurity and degradation product standards are unavailable. The bias for individual, unknown impurities obtained by the two methods was not more than the acceptance criterion of ±0.03 and the bias for total impurities was within the acceptance criterion of ± 0.10.
The amount of each impurity [% m/m] present in the test solution (morphine concentration about 2.5 mg/mL) was calculated using the peak due to morphine obtained with reference solution (diluted test solution to about 0.005 mg/mL, i.e. 0.2% solution relative to test solution) as external reference. For the purpose of the study (API fingerprinting) no peak was disregarded.
Robustness validation
Within method validation, suitability of the chromatographic system was demonstrated using mixed standard solution, containing related substances specified in the Ph.Eur monographs on morphine hydrochloride trihydrate (04/2008:0097) and morphine sulfate pentahydrate (04/2008:1244):
10 impurity A (codeine), impurity B (2,2'-bimorphine), impurity C (oripavine), impurity D (10S-hydroxymorphine), impurity E (morphinone), and impurity F (morphine N-oxide), as well as other naturally occurring coextracted (commercially available) alkaloids: thebaine, noscapine, and papaverine.
Specificity was demonstrated by showing that the peaks were acceptably resolved, by performing peak purity tests using diode array detector and mass spectrometry. Additionally, specificity was proved by comparing the impurity profiles of API samples obtained with the pharmacopeial method for determination of related substances of morphine, described in the relevant Ph.Eur monographs.
Since robustness testing of analytical methods 20 requires extensive experimental work (where intentional changes in experimental conditions are made and studied), here an accurate and rational assessment of the robustness of the method was done by use of chemometrics. Minor changes in experimental factors values were made by performing a set of 12 experiments defined by the 2 2 full factorial quadratic design of experiments ( Table 2 ). The following method parameters were altered in order to test the robustness: buffer concentration (x 1 ), in a range ±1 mM from the proposed concentration of 5 mM (corresponding to maximum 20% variation of the system suitability criteria 21, 22 ) and buffer pH (x 2 ) , in a range ± 0.2 pH value from the proposed pH = 10.2 (corresponding to recommended maximum variation of pH. 20 ) These method parameters were determined as critical during method optimization by use of chemometrics. System suitability solutions were analyzed to assess if these changes had a significant effect on the defined method parameters. The chromatographic response was assessed through the critical resolutions (between morphine and impurity E and morphine and impurity B) and the retention factor of impurity F.
System suitability criteria for the method should be fulfilled, i.e. the critical resolutions between morphine and impurity E and morphine and impurity B should be above 2.0 and the retention factor of impurity F should be above 1.0. Table 2 and Figure 4 summarize the results of the robustness study. The small changes in buffer concentration (± 1 mM) and pH of the mobile phase (± 0.2) did not change significantly the chromatographic responses defined within the acceptance criteria ( Figure 3 ). The critical resolutions between morphine and impurity E and morphine and impurity B remained above 2.0 (Figures 3a and 3b ) and the retention factor of impurity F was around the defined value of 1.0 (Figure 3c ). However, the retention factor of impurity F was found to be affected at low buffer concentration (4 mM) and high pH values (pH 10.4), especially when the experimental factors were changed simultaneously. Therefore, it is recommended to maintain buffer pH at 10.2 ± 0.05 and buffer concentration at 5 ± 0.5 mM.
Identification of morphine impurities using mass spectrometry
The starting material and known impurities under investigation are alkaloids containing basic nitrogen, which makes them preordained for electrospray ionization in positive ionization mode. In order to test mass spectrometer selectivity, this method was optimized with analysis of mixed standard solution containing all pharmacopeia impurities and related substances listed in Table 3 : morphine N -oxide (impurity F), 10-S -hydoxymorphine (impurity D), morphinone (impurity E), 2,2' bimorphine (impurity B), oripavine (impurity C), codeine (impurity A), papaverine, phebaine, and noscapine. Figure 4 shows a UV chromatogram of all the impurities present in mixed standard solution. 
Experiment
Parameters of the method (factors) Chromatographic descriptors (responses) The first challenge for this mass spectrometry method was to distinguish morphine N -oxide (impurity F) from 10-S -hydoxymorphine (impurity D), which are structural isomers with molar mass 301. Namely, impurity D differs from morphine by one hydroxyl group attached to position C-10 on morphine B ring opposite from impurity F, which includes one oxygen atom attached to nitrogen (position 17) and forms morphine N-oxide.
According to the obtained mass spectra from experimental data, impurity F (molecular weight 301, impurities F and D are structural isomers they can be distinguished by their fragmentation pathways. In the absence of specific standards for these impurities, for the MS part of this method information from mass spectra was used as a verification tool and it was defined that impurity F occurs at a retention time of about 2.83 and impurity D occurs at a retention time of about 5.4 min.
Additionally, morphine base (MoB), morphine sulfate (MoS), and morphine hydrochloride (MoH) samples were analyzed and effort was made to identify the following unknown impurities/morphine related products and keeping in mind the mass spectrometry results, the most probable structures of these impurities were suggested. All discussed fragments of unknown impurities are summarized in Table 4 . As additional confirmation of the X1 structure, unknown impurity X2 structure was suggested. This impurity at RRt = 0.75 has a molecular ion peak m/z 388, which points to the morphine-related structure diacethyloxymorphine. Furthermore, this structure shows fragments m/z 344, which indicates the monoacethyl- confirmed by peaks m/z 503 and m/z 269, respectively. The suggested structure of this impurity differs from a bimorphine structure by 48 amu. These observations lead to the conclusion that this impurity with m/z 520 most probably consists of two morphine structures, one with detached CH 3 CH 2 NH-group and saturated C-C bonds on both morphine B rings.
Impurity X5 at RRt = 1.18 (which is very close retention time to the main compound, morphine) shows the same full mass spectra and fragments as morphine. The fragmentation of morphine and most abundant ions are explained above and confirmed by the literature.
24−30 Difference in retention time of morphine and unknown impurity X5 (higher retention) indicates that the unknown compound is less polar than morphine, which most probably originates from different arrangement of hydroxyl groups or substitution of less polar groups with the same mass as OH groups on morphine rings B and A. All of the above-mentioned information suggests that morphine and impurity X5 are structural isomers with the same molar mass; the same fragments but different polarity equals different retention time.
A group of impurities at RRt 1.24 (X6), 1.27 (X7), and 1.28 (X8) points to dihydromorphone-like structures or, in other words, dihydromorphone structural isomers, with the same m/z 284 (dihydromorphone molecular mass is 283) and the same fragmentation until MS 3 but different polarity due to different arrangement of the same substituent, which in this case can only be different substitution of the -OH group on the dihydomorphone structure.
Unknown impurity X9 at RRt 1.14, present only in one MoB sample, 7 shows mass spectra with m/z 358. In MS 2 this impurity is followed by loss of 72 amu to form only one most abundant peak ion m/z 286 (morphine), which is followed by fragmentation, the same as morphine fragmentation in MS 3 . The most probable structure of this impurity is morphine with substituent of 72 amu (CH3-CH-CH 2 CH 2 OH) on position 2 on morphine A ring.
Peaks at RRt 1.48, 1.53, and 1.57 (X10, X11, and X12) are probably bimorphine-like structures with saturated double bonds on morphine rings A or C. These three impurities in the full mass spectra range show m/z 572, which is a difference of only one saturated double bond from the bimorphine original structure. It is assumed that this saturation influences the retention time (different from all other bimorphine-like structures discussed above). As all previously discussed bimorphines, in the first fragmentation step all of the three compounds lose 17 amu, followed by loss of 286 to form m/z 176. Unknown structures X10-12 differ in intensity abundance of ion peaks in MS 2 and therefore it can be concluded that they are structural isomers.
Unknown impurity X13 with RRt = 0.82 shows a molecular ion peak with m/z 327, which in MS 2 shows fragments, such as m/z 133, which is probably the most stable metoxybenzyl radical (formed with loss of 194 amu) and peaks with m/z 284 as a result of a loss of 43 amu in the form of a CH 3 C= O group. The presence of metoxybenyl radical (note that monoacetyl group is attached on the morphine ring C) plays a crucial role in morphine structure fragmentation 21, 22, 30 and the mass spectra of this impurity indicate that this impurity is a monoacetylmorphine derivate.
In this work, a suitable "MS friendly" HPLC method for separation and identification of morphine and its known and unknown related substances and possible degradation products was developed and successfully employed for origin determination of morphine samples using pattern recognition techniques. 7 That part of the research proved the applicability of the method and highlighted its advantages over the existing pharmacopoeial HPLC method for determination of related substances of morphine, 10 regarding authentication and prevention of falsification.
The method for separation of morphine-related compounds proposed by Ph. Eur, using anionic ionpairing agents at acidic pH to avoid peak tailing, is not convenient for coupling with mass spectrometer due to the nonvolatility of the ion-pair reagents. In order to avoid use of ion-pairing agents, we searched for an alternative mobile phase. Due to the basic nature of morphine impurities (morphinane core), good separation was obtained at alkaline pH, where the amine group would not be ionized. This is generally not possible with bonded silica-based columns because of the instability of the silica matrix at alkaline pH.
20−22 A reversedphase columns with bidentate C18-C18 bonding technology that prevents interactions between noncharged basic compounds with the underlying silica at high pH was chosen as a stationary phase. 31 Some of the mobile phase buffer options for high pH included trifluoroacetic acid (TFA), trichloroacetic acid (TCA), ammonium acetate (AmAc), and ammonium formate (AmF) in combination with ammonia. TCA and AmAc did not provide a satisfactory solution, unlike TFA, but in this case the large ion reduced the sensitivity of the mass spectrometer. The optimal chromatographic and mass spectrometry conditions were obtained using AmF in combination with ammonia for pH adjustment. As for the choice of a UV wavelength, although morphine-related compounds have absorption maxima around 283 nm, 230 nm was used for detection in order to expose morphine N-oxides. An additional step of heating the mobile phase and sample mixture prior to ionization (heated electrospray ionization (HESI)) was used to maintain a high flow rate of the mobile phase of 1 mL/min in order to achieve faster analysis time and at the same time accomplish vaporization of the mobile phase before ionization. During method optimization, both ESI and HESI modes were tested and it was concluded that the additional heating of the probe does not induce additional degradation of morphine.
Using DoE results, the separation of all the impurities was obtained with an optimized gradient elution with methanol and 5 mM ammonium formate, pH adjusted to 10.2. All compounds were fully resolved and eluted within 20 min and satisfactory ionization and mass spectrometer sensitivity were achieved. After method validation, closer examination of the results obtained from mixed standard solutions presented in Table 3 suggests that all morphine-related compounds undergo similar fragmentation patterns as morphine, after their side chains or function groups detach. In previous years, soft ionization methods were intensively used for investigation of morphine and its metabolites, 24−34 versus the electron impact (EI) mass spectra of morphine and morphine-related compounds, which were elaborated at the end of the last century. Methanol (MeOH, HPLC grade), sodium heptanesulfonate (pa), and phosphoric acid (pa) were purchased from Merck, Darmstadt, Germany. Acetic acid (pa), ammonium formate (pro analysis), and formic acid (pa)
were purchased from Sigma-Aldrich (Steinheim, Germany). Water (highly purified) was obtained with a TKA-LAB Reinstwasser system (Niederelbert, Germany).
Sample preparation
Mixed standard solution was prepared by dissolving 5 mg of morphine for system suitability CRS in MeOH, adding 100 µ L of the corresponding methanol stock solution (concentration of 1 mg/mL) of codeine (Ph.Eur impurity A), thebaine, papaverine, and noscapine, and diluted to 2 mL with MeOH. Sample solution was prepared by dissolving about 0.125 g of the substance to be examined in MeOH and diluted to 50 mL with the same solution. Reference solution, used for the calculation of each impurity's content, 7 was prepared by dilution of 1.0 mL of the test solution to 100.0 mL with MeOH and further dilution of 2.0 mL of this solution to 10.0 mL with MeOH. All samples and standards were prepared in duplicate. Each sample preparation was injected twice in the HPLC system. Six replications of each quantification standard were injected on a daily basis to confirm repeatability of the HPLC system. In order to check the performance of the HPLC system, prior to every analysis system suitability solution containing all known impurities was analyzed. Standards, samples, and system suitability solutions used for method validation were prepared and injected as recommended by ICH guidelines Q2 R1. 
Instrumentation and LC-MS conditions
The analysis was performed on a Thermo Scientific Dionex Ultimate 3000 UHPLC-UV-DAD system consisting of a Thermo Scientific Dionex Ultimate 3000 pump, Thermo Scientific Dionex Ultimate 3000 injector, Thermo Scientific Dionex Ultimate 3000 Column Thermostat Compartment, and Thermo Scientific Dionex Ultimate 3000 diode array detector associated with a Thermo Scientific LTQ XL linear ion trap mass spectrometer equipped with a HESI probe and controlled by Chromeleon 5.0 and Xcalibur 2.0 software. The separation of the detected impurities was achieved on a Zorbax Extend C18 column (Agilent Technologies), 250 mm × 4.6 mm i.d., and 5 µm particle size. Elution was performed at flow rate of 1.0 mL/min, using mobile phase consisting of MeOH and ammonium formate buffer (5 mM; pH 10.2 adjusted using 25% ammonia solution)
with the following gradient: 0-1 min 15% MeOH; 1-5 min from 15% to 50% MeOH; 5-15 min from 50% to 75% MeOH; 15-20 min 75% MeOH; 20-25 min from 75% to 15% MeOH; 25-35 min 15% MeOH. The injection volume was 10 µ L, the column temperature was maintained at 35
• C, and detection was carried out at 230 nm.
The ESI probe needle temperature was 350
• C, and the ion transfer tube was 325
• C under sheath gas (nitrogen) at 50 psi and auxiliary gas helium at 10 psi. Mass spectra were recorded in the range of 50-800 m/z, with maximum accumulation time of 500 ms. The collision-induced fragmentation was performed in an ion trap using helium as collision gas at 3.5 eV. The specified impurities were confirmed by retention times and UV spectra and all detected impurities (specified and unknown) were identified using their mass spectra and fragmentation patterns.
Chemometrics
MODDE 10.1 software for DoE and optimization (Umetrics, Umea, Sweden) was used for optimization of the experimental factors through an appropriate factorial design. The designed experiments were conducted on a mixed standard solution. DoE was used to assess the influence of the ionic strength and the pH of the mobile phase buffer on chromatographic responses (2 2 CCC DoE) and for the robustness testing during method validation (2 3 CCC DoE).
Conclusion
The discussed results obtained in this study demonstrate that the proposed LC-DAD-HESI-MS method used for impurity profiling of MoB, MoH, and MoS API samples represents a useful tool for online characterization of known and unknown morphine-related impurities and degradation products. This LC-MS n method has the ability to generate characteristic impurity fragmentation patterns, which consequently can be used as an advanced tool for achieving improved identification performances. According to MS spectra, tentative structures for detected unknown impurities were proposed, confirming that all detected impurities are structurally related to morphine. Therefore, the suggested LC-MS method provides a broad 'analytical window' in relation to the identified impurities, which allows authenticity verification of APIs from various manufacturers.
